Dr Reddy's Launches Insomnia Drug in US; Glenmark Gets FDA Nod - The New Indian Express

Dr Reddy's Launches Insomnia Drug in US; Glenmark Gets FDA Nod

Published: 16th April 2014 03:34 PM

Last Updated: 16th April 2014 03:34 PM

Pharma major Dr Reddy's Laboratories today said it has launched a drug to treat insomnia in the US market, following approval by the Food & Drug Administration (FDA).

The company has started selling 1 mg, 2 mg and 3 mg tablets of Eszopiclone, a generic version of Lunesta, a sedative drug that is used for the treatment of insomnia.

Sunovion Pharmaceuticals Inc is the owner of the Eszopiclone drug.

According to IMS Health, Lunesta tablets and generics combined had US sales of about USD 887 million for the 12 months ended January 2014, Dr Reddy's said in a filing with the stock exchanges.

Dr Reddy's said 1 mg tablets are available in bottle counts of 30, while 2 mg and 3 mg tablets will be sold in bottle counts of 100.

Dr Reddy's shares traded at Rs 2,542.95 on the BSE in afternoon trade, down 1.54 per cent.

Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd, said in a separate statement that it has been granted final abbreviated new drug approval from the FDA for Eszopiclone tablets.

"Glenmark will commence distribution of the product immediately. The approval is for the 1 mg, 2 mg and 3 mg tablets," Glenmark said in the statement.

Glenmark shares quoted at Rs 582.40 on the BSE, up 0.18 per cent.

comments powered by Disqus

Disclaimer: We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the NIE editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.


Read More



follow us Mobile Site iPad News Hunt Android RSS Tumblr Linekin Pinterest Youtube Google Plus Twitter Facebook